Sasagawa I, Nakada T, Hashimoto T, Ishigooka M, Kubota Y, Hirano K, Hirano J, Suzuki Y
Department of Urology, Yamagata University, School of Medicine, Japan.
Urol Int. 1992;48(2):181-3. doi: 10.1159/000282326.
Serum concentrations of prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostatic specific antigen (PSA) were measured in 31 hemodialysis patients without clinical signs of malignant disease. PAP, gamma-Sm and PSA levels in serum were not significantly different between control and hemodialysis groups. A significant reduction in these tumor markers was not found after dialysis treatment. This indicates that the measurement of PAP, gamma-Sm and PSA in serum is useful for the detection of prostatic cancer in patients undergoing hemodialysis.
